Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva with Chemotherapy in Resectable Stage IIIA/IIIB NSCLC
NCT00063258Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2003
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2003; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00063258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063258.